Novartis to Buy Excellergy for up to $2 Billion

Novartis targets Xolair successor in buyout of startup Excellergy

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine.

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Novartis to buy Excellergy for up to $2B to boost allergy portfolio

Novartis (NVS) to acquire Excellergy for up to $2B, adding early-stage anti-IgE allergy drug Exl-111.

Novartis to buy Excellergy for up to $2 billion

Swiss pharma company Novartis said it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases     - Lead asset Exl-111 builds on proven IgE biology with a...